This Multibagger Drugmaker Stock Rises 848% in 3 Years: How a New Antibiotic Changed Everything

This multibagger drugmaker stock has turned Rs 1 lakh into roughly Rs 9.48 lakh in three years. One antibiotic-focused pharma company delivered a 3-year return of 847.92%, the third-best performance in a screen of 101 large-cap and mid-cap NSE shares, as of 10 September 2026.

The company is Wockhardt Ltd (NSE: WOCKPHARMA), the Mumbai-based drugmaker that spent more than a decade building new antibiotics for drug-resistant infections. The Wockhardt share price traded near Rs 2,236 on 10 September 2026, down about 0.6% from the previous close of Rs 2,248.80, giving it a market cap of approximately Rs 36,586 crore. Three years ago, the multibagger drugmaker stock changed hands at around Rs 236.

Click Here – Get Free Investment Predictions

How Much Has This Multibagger Drugmaker Stock Returned?

The short answer: approximately 848% in three years, which places this multibagger drugmaker stock at rank 3 out of 101 stocks screened. The rise is genuine price appreciation. There was no stock split or bonus issue in the period, only equity raises through qualified institutional placements that added shares rather than inflating the price.

The shorter periods show that the momentum has not faded. The multibagger drugmaker stock is up 17.13% in one month and 81.29% in six months, both ranking 9th in the same screen of 101 shares.

Period	Return	Rank (out of 101)
1 Month	17.13%	9
6 Months	81.29%	9
1 Year	48.15%	33
3 Years	847.92%	3
5 Years	437.20%	20

The 5-year return of 437.20% is lower than the 3-year figure because the multibagger drugmaker stock was falling heavily between 2021 and 2023, when the company was reporting large losses. The real rally began in late 2023, which is why the three-year window captures the full turnaround.

On the 52-week chart, the Wockhardt share price has swung between a low of Rs 1,086.70, hit on 23 March 2026, and an all-time high of Rs 2,422.30, touched on 1 June 2026. This multibagger drugmaker stock currently sits about 8% below that peak and more than double the March low.

Why Did This Multibagger Drugmaker Stock Rise So Much?

Three forces powered the rally: a first-of-its-kind US approval for a new antibiotic, a clean-up of the balance sheet through fresh equity, and a swing from years of losses to steady profits. Each one removed a major doubt that had kept investors away from this multibagger drugmaker stock for years.

Zaynich Became the First Indian NCE Approved by the US FDA

The single biggest trigger came on 30 May 2026, when the US Food and Drug Administration approved Zaynich, a combination of cefepime and zidebactam. It is the first new chemical entity fully developed by an Indian pharma company to win US approval. The drug treats complicated urinary tract infections, including pyelonephritis, caused by drug-resistant Gram-negative bacteria.

On 1 June 2026, the multibagger drugmaker stock jumped about 19% from Rs 2,031.40 to its record high of Rs 2,422.30. The stock had already gained around 17% in the prior week after India's drug regulator granted import and marketing authorisation for Zaynich. Management has pointed to a US opportunity estimated at approximately USD 9 billion, with around 2.8 million antimicrobial-resistant infections recorded in the country every year.

A Long Pipeline of Milestones Built Confidence

Zaynich did not arrive out of nowhere. In January 2025, the multibagger drugmaker stock rose about 10% after the drug showed 96.8% efficacy in its Phase III study. The US FDA accepted the new drug application in late 2025, and on 1 December 2025 the multibagger drugmaker stock surged 19% on volumes roughly ten times the average.

Earlier, in October 2024, the company received a favourable expert committee recommendation in India for Miqnaf (nafithromycin), a pneumonia antibiotic. It also filed insulin aspart with the Indian regulator. Wockhardt now has six antibiotics in clinical development or commercialisation, and all six carry the US Qualified Infectious Disease Product designation.

The early leg of the rally was just as sharp. Between November 2023 and October 2024, the multibagger drugmaker stock climbed about 384%, from around Rs 250.50 to Rs 1,212.55, its highest level in eight years at the time. That run was powered by pipeline news and a Q1 FY25 EBITDA jump of about 216% to Rs 100 crore.

Fresh Capital Cleaned Up the Balance Sheet

The company behind this multibagger drugmaker stock raised Rs 480 crore through a QIP in March 2024 at about Rs 517 per share, followed by a Rs 1,000 crore QIP launched in November 2024. This capital helped fund the antibiotic programme and cut debt. Debt to equity has eased from 0.68 in FY24 to 0.46 in FY26, and a credit rating agency upgraded the company's bank facilities on 21 May 2026.

The Business Swung Back to Profit

After four straight years of losses, Wockhardt reported a full-year net profit of Rs 199 crore in FY26, compared with a loss of Rs 57 crore in FY25 and a loss of Rs 472 crore in FY24. For a multibagger drugmaker stock, that shift from cash burn to earnings was the fundamental proof that investors were waiting for.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Financial Performance of This Multibagger Drugmaker Stock

The quarterly numbers show the turnaround in detail. Revenue has risen from Rs 758 crore in the June 2025 quarter to Rs 960 crore in the June 2026 quarter, while EBITDA more than doubled.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	EBITDA Margin	Net Profit (Rs Cr)	EPS (Rs)
Jun 2025	758	92	12.1%	-108	-5.53
Sep 2025	803	199	24.8%	82	4.81
Dec 2025	913	202	22.1%	61	3.61
Mar 2026	1,010	270	26.7%	164	10.22
Jun 2026	960	223	23.2%	107	6.55

In the Q1 FY27 results, the company reported operating revenue of approximately Rs 929 crore, up about 26% year on year, and a net profit of Rs 107 crore against a loss of Rs 108 crore a year earlier. The biosimilars business grew about 112% to Rs 236 crore, and innovative products made up around 27% of total revenue.

The mix of the business is also shifting. Exports made up about 77% of FY25 revenue, and the new antibiotic brands give this multibagger drugmaker stock a higher-margin growth engine alongside its generics and biosimilars portfolio in Europe, the UK and emerging markets.

On a yearly basis, revenue grew from Rs 3,074 crore in FY25 to Rs 3,484 crore in FY26. EBITDA climbed from Rs 455 crore to Rs 678 crore over the same period. Operating cash flow recovered to Rs 390 crore in FY26 from a negative Rs 22 crore a year earlier.

Even so, the Wockhardt share price did not reward the Q1 FY27 numbers right away. The multibagger drugmaker stock fell 4.44% to Rs 1,931.20 on 10 August 2026, as investors weighed the costs of launching Zaynich in the US and Europe. It has since recovered to around Rs 2,236.

Valuation and Shareholding Check

This multibagger drugmaker stock now trades at a steep premium to its sector, and much of the future Zaynich revenue is already priced in.

Metric	Value
Current Market Price	Approximately Rs 2,236
Market Cap	Approximately Rs 36,586 Cr
P/E Ratio	88.37
Industry P/E	38.26
P/B Ratio	7.41
ROE	5.75%
Debt to Equity	0.45
52-Week High / Low	Rs 2,422.30 / Rs 1,086.70
Promoter Holding (Jun 2026)	49.08%

A PE of about 88 is more than double the industry average of around 38, while the ROE of 5.75% remains modest. That gap tells you the market is valuing this multibagger drugmaker stock on what Zaynich could earn from 2027 onwards, not on current profits.

Promoter holding has stayed stable at approximately 49.08% across the last five quarters. Institutional holding stood at about 16.47% in June 2026, slightly lower than 18.31% a year earlier, which suggests some mutual funds booked profits during the rally. Small-cap and focused funds still hold positions in the Wockhardt share.

Key Risks for This Multibagger Drugmaker Stock

A 848% rally leaves little room for disappointment. Investors holding or tracking this multibagger drugmaker stock should weigh these risks.

Launch execution: The US launch of Zaynich is targeted for the first quarter of 2027. The company is hiring 35 to 40 infectious disease specialists, and global commercialisation will raise costs before revenue arrives. Hospital antibiotic uptake is often slow, because doctors reserve new drugs for the toughest cases. For a multibagger drugmaker stock priced for success, a slow start could hurt.

Valuation risk: At a PE near 88, any delay in US sales, a weak launch quarter or a slower European approval could trigger a sharp correction. The multibagger drugmaker stock already showed this sensitivity when it fell more than 4% after the Q1 FY27 results.

Regulatory dependence: A European decision on Zaynich is expected around December 2026 or January 2027. Any adverse outcome or request for more data would hit sentiment around the multibagger drugmaker stock. Past US FDA compliance issues at the company's plants also remain a reminder that manufacturing inspections matter.

Volatility: This multibagger drugmaker stock fell to Rs 1,086.70 as recently as March 2026 before more than doubling within about ten weeks. Swings of this size can work in both directions, and promoter share pledging has been a concern in the past.

Download the Univest iOS App or Univest Android App to track the Wockhardt share price live

Wockhardt Share: Analyst View

The analyst view on this multibagger drugmaker stock is constructive but cautious on valuation. A domestic brokerage said the US approval is expected to improve profitability significantly and puts the company on a different trajectory. The broad view is that Zaynich changes the long-term earnings profile of the business, but the timing of US and European sales will decide the next leg of the Wockhardt share price.

Wockhardt Share Price Target

As of 10 September 2026, no verified brokerage Wockhardt share price target is available from our research. In the absence of a published target for this multibagger drugmaker stock, the key levels are the all-time high of Rs 2,422.30 on the upside and the 52-week low of Rs 1,086.70 on the downside. A sustained move above Rs 2,422 would need fresh triggers such as the European approval or early US sales data.

On the downside, the post-results low of about Rs 1,931 acts as a nearer reference level. Any future Wockhardt share price target from analysts is likely to hinge on peak Zaynich sales estimates, so investors should track launch updates each quarter.

Conclusion

This multibagger drugmaker stock turned a long bet on antibiotic research into an 848% gain over three years. The US FDA approval of Zaynich, a return to profit and a stronger balance sheet together explain why the Wockhardt share price rose from around Rs 236 to over Rs 2,200.

The next phase is harder. The multibagger drugmaker stock now trades at a PE near 88 and depends on a successful US launch in 2027. Long-term investors may prefer staggered buying on dips and close tracking of launch milestones, while new investors should size positions carefully given the volatility.

Frequently Asked Questions

Which multibagger drugmaker stock rose 848% in 3 years?

Ans. Wockhardt Ltd (NSE: WOCKPHARMA) is the multibagger drugmaker stock that returned approximately 847.92% over three years as of 10 September 2026. It ranked 3rd among 101 large-cap and mid-cap NSE stocks screened.

Why did the Wockhardt share price rise so much?

Ans. The rally was driven by the US FDA approval of its novel antibiotic Zaynich on 30 May 2026, a swing from losses to profit and lower debt after two QIPs. The approval alone lifted the multibagger drugmaker stock about 19% in a single session.

What is Zaynich?

Ans. Zaynich is a combination of cefepime and zidebactam used to treat complicated urinary tract infections caused by drug-resistant Gram-negative bacteria. It is the first new chemical entity from an Indian pharma company to receive US FDA approval. It is also the main reason this multibagger drugmaker stock has re-rated.

When will Zaynich launch in the US?

Ans. Wockhardt is targeting a US launch of Zaynich in the first quarter of 2027. A European approval decision is expected around December 2026 or January 2027. The launch is the key trigger for this multibagger drugmaker stock.

What were Wockhardt Q1 FY27 results?

Ans. Wockhardt reported operating revenue of approximately Rs 929 crore in Q1 FY27, up about 26% year on year. Net profit was Rs 107 crore against a loss of Rs 108 crore in the same quarter last year.

What is the 52-week high and low of Wockhardt?

Ans. The 52-week high is Rs 2,422.30, touched on 1 June 2026, and the 52-week low is Rs 1,086.70, recorded on 23 March 2026. The multibagger drugmaker stock traded near Rs 2,236 on 10 September 2026.

Is this multibagger drugmaker stock overvalued?

Ans. On current earnings the valuation is stretched, with a PE of about 88 against an industry PE of around 38. The price reflects expected Zaynich sales, so any launch delay could lead to a sharp correction.

What is the Wockhardt share price target?

Ans. No verified brokerage Wockhardt share price target was available as of 10 September 2026. Investors can track the all-time high of Rs 2,422.30 and the 52-week low of Rs 1,086.70 as key levels, and should consult a SEBI-registered advisor before investing.